COMMUNIQUÉS West-GlobeNewswire

ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025
MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II [...]
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
26/09/2025
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a [...]
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
26/09/2025
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein [...]
Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
26/09/2025
Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have an interest rate [...]
Harrow to Acquire Melt Pharmaceuticals
26/09/2025
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to [...]
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
26/09/2025
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated [...]
ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26/09/2025
MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II [...]
RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025
26/09/2025
LOS ANGELES, Sept. 26, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide
26/09/2025
Now Operating in 19 States Nationwide Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc [...]
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
26/09/2025
September 26, 2025 News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “ [...]
Concept Life Sciences Expands Integrated Drug Discovery Facilities
26/09/2025
Establishes one of the UK’s largest drug discovery research sites Site officially opened by local MP Jonathan Pearce CHAPEL-EN-LE-FRITH, United Kingdom, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences, a [...]
Fangzhou’s ‘XingShi’ LLM Featured by Nature News and Xinhua, Showcasing AI Innovation in Chronic Disease Care
26/09/2025
SHANGHAI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its “XingShi” Large Language Model (“XS LLM”) was [...]
Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics
26/09/2025
Paris, le 26 septembre 2025 – BioLabs Hôtel-Dieu, en partenariat avec Ipsen, annoncent aujourd'hui que DETERA Therapeutics s'est vu décerner le Golden Ticket Ipsen 2025 . Ce prix offre un an d'accès gratuit à un [...]
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
26/09/2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products [...]
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
26/09/2025
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of Pluvicto TM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC NATALEE five-year analysis of [...]
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
26/09/2025
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
26/09/2025
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: [...]
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie
26/09/2025
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie Nantes, le 26 septembre 2025, 7 heures – OSE Immunotherapeutics SA ( ISIN [...]
uniQure Announces Pricing of Upsized $300 Million Public Offering
26/09/2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]

Pages